The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
09-Aug-16
$NA
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Target:
Bionomics Limited
![flag not available](https://www.greenhill.com/sites/default/files/n_a_flag.gif)
Advised ASX-listed Bionomics, a clinical stage biopharmaceutical company focused on the treatment of serious central nervous system disorders and cancer, on a consultation process with shareholders following calls for Board change, leading to the formation of a shareholder working group of leading institutional investors and company-led Board renewal.
15-Dec-10
$12.9 billion
![USA/Switzerland U.S.A., Swiss flags](https://www.greenhill.com/sites/default/files/usa_swiss.gif)
Target:
Alcon, Inc.
![Switzerland Switzerland flag](https://www.greenhill.com/sites/default/files/switzerland.gif)
Acquiror:
Novartis AG
Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company